In yesterday’s Wall Street session, Aytu BioPharma Inc. (NASDAQ:AYTU) shares traded at $0.19, down -1.28% from the previous session.
AYTU stock price is now -2.86% away from the 50-day moving average and -58.82% away from the 200-day moving average. The market capitalization of the company currently stands at $12.77M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target of $11, Cantor Fitzgerald recently initiated with Overweight rating for Aytu BioPharma Inc. (NASDAQ: AYTU). On May 29, 2020, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $3.
In other news, Disbrow Joshua R., Chief Executive Officer bought 112,371 shares of the company’s stock on Dec 19. The stock was bought for $25,047 at an average price of $0.22. Upon completion of the transaction, the Chief Executive Officer now directly owns 1,231,877 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19, Chief Commercial Officer PYSZCZYMUKA GREG bought 100,000 shares of the business’s stock. A total of $24,480 was incurred on buying the stock at an average price of $0.24. This leaves the insider owning 182,056 shares of the company worth $34590.64. A total of 4.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AYTU stock. A new stake in Aytu BioPharma Inc. shares was purchased by ALYESKA INVESTMENT GROUP, L.P. during the first quarter worth $278,000. SABBY MANAGEMENT, LLC invested $234,000 in shares of AYTU during the first quarter. In the first quarter, WALLEYE CAPITAL LLC acquired a new stake in Aytu BioPharma Inc. valued at approximately $108,000. AYRTON CAPITAL LLC acquired a new stake in AYTU for approximately $84,000. CVI HOLDINGS, LLC purchased a new stake in AYTU valued at around $26,000 in the second quarter. In total, there are 49 active investors with 14.20% ownership of the company’s stock.
On Thursday morning Aytu BioPharma Inc. (NASDAQ: AYTU) stock kicked off with the opening price of $0.1876. During the past 12 months, Aytu BioPharma Inc. has had a low of $0.15 and a high of $1.59. As of last week, the company has a debt-to-equity ratio of 0.42, a current ratio of 1.00, and a quick ratio of 0.80. The fifty day moving average price for AYTU is $0.1914 and a two-hundred day moving average price translates $0.4500 for the stock.
The latest earnings results from Aytu BioPharma Inc. (NASDAQ: AYTU) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.49, missing analysts’ expectations of -$0.37 by -0.12. This compares to -$1.09 EPS in the same period last year. The net profit margin was -83.20% and return on equity was -127.80% for AYTU. The company reported revenue of $27.66 million for the quarter, compared to $21.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.3 percent. For the current quarter, analysts expect AYTU to generate $24.3M in revenue.
Aytu BioPharma Inc.(AYTU) Company Profile
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
